Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Imatinib in Intermediate Risk CML
NCT00510926Phase 2Completed
- Sponsor
- Alma Mater Studiorum – Università di Bologna
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in chronic myeloid leukemia (CML), sponsored by Alma Mater Studiorum – Università di Bologna. Started Jan 2004; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00510926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00510926.